Tech Company Financing Transactions
Amygdala Neurosciences Funding Round
Amygdala Neurosciences secured a $5.6 million funding round on 11/19/2019. Investors included private investors.
Transaction Overview
Company Name
Announced On
11/19/2019
Transaction Type
Venture Equity
Amount
$5,600,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to conduct Phase 2 clinical studies to assess ANS-6637 as a treatment for opioid, alcohol, and smoking/nicotine use disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
509 Hale St.
Palo Alto, CA 94301
USA
Palo Alto, CA 94301
USA
Phone
Undisclosed
Website
Email Address
Overview
Amygdala Neurosciences is developing ANS-6637 for the treatment of substance use disorder. NIH funded Phase-2 studies for opioid and alcohol use disorders will begin in 2019. We are also planning to start a Phase-2 study for smoking cessation and studies to support cocaine use disorder development in 2019.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Lou Lange
Chief Executive Officer
Peter Strumph
Chief Financial Officer
Adrienne MacMillan
Chief Medical Officer
Mack Mitchell
Chief Scientific Officer
Ivan Diamond
VP - Bus. Development
Brent Blackburn
Browse more venture capital transactions:
Prev: 11/19/2019: StimAire venture capital transaction
Next: 11/19/2019: Underdog Pharmaceuticals venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs